Neuralgene announces partnership with Precision StemCell of Bogota, Colombia to begin testing of PRCN-829.
Neuralgene initial animal testing demonstrates safety of their gene therapy platform. Neuralgene announces a larger study in the ALS mouse model to evaluate efficacy of PRCN-829 will begin by mid 2013.
Neuralgene is partnering with Precision StemCell in Bogota, Colombia to begin testing with genetically engineered stem cell therapy for the treatment of neurodegenerative disorders such as ALS. Precision StemCell will begin animal testing using cultured adipose derived mesenchymal stem cells and neural reprogrammed stem cells which have been genetically engineered using Neuralgene’s PRCN-829 neurotropic multi-gene AAV gene therapy.